Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

Key Points

• Deutsche Bank AG acquired 241,447 Upstream Bio shares during the second quarter, valued at approximately $1.67 million and representing about 0.44% of the company.
• Several other institutions also built positions, including UBS, which increased its stake by 563.4% to 1.81 million shares, while Jennison Associates, Pictet Asset Management, Walleye Capital and Arrowstreet Capital initiated positions.
• Upstream Bio shares opened at $6.69, near their one-year low, while analysts held a consensus “Hold” rating with a $29.67 price target. The company slightly beat quarterly EPS expectations but remains unprofitable, reporting $0.77 million in revenue and a projected full-year loss of $2.86 per share.

Deutsche Bank AG purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 241,447 shares of the company's stock, valued at approximately $1,671,000. Deutsche Bank AG owned about 0.44% of Upstream Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the company. Jennison Associates LLC acquired a new position in Upstream Bio in the 4th quarter valued at $7,842,000. Pictet Asset Management Holding SA purchased a new stake in shares of Upstream Bio during the fourth quarter worth $20,991,000. UBS Group AG raised its position in shares of Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company's stock valued at $49,039,000 after buying an additional 1,533,972 shares during the last quarter. Walleye Capital LLC purchased a new stake in Upstream Bio during the 2nd quarter valued at about $3,450,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Upstream Bio during the 1st quarter valued at about $1,666,000.

Analyst Ratings Changes

UPB has been the topic of a number of research reports. Wall Street Zen lowered shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Mizuho reduced their price objective on Upstream Bio from $51.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, May 14th. HC Wainwright assumed coverage on Upstream Bio in a research note on Wednesday, June 3rd. They set a "buy" rating and a $36.00 price objective on the stock. Weiss Ratings raised shares of Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 17th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $29.67.

Upstream Bio Price Performance

Shares of UPB opened at $6.69 on Friday. The firm has a 50-day simple moving average of $6.95 and a two-hundred day simple moving average of $8.31. The stock has a market cap of $366.41 million, a PE ratio of -2.31 and a beta of 1.26. Upstream Bio, Inc. has a 1-year low of $5.85 and a 1-year high of $33.68.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. As a group, sell-side analysts expect that Upstream Bio, Inc. will post -2.86 earnings per share for the current fiscal year.

Upstream Bio Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

Want to see what other hedge funds are holding UPB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Upstream Bio, Inc. (NASDAQ:UPB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source